XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scien
06 September 2007 - 5:56PM
PR Newswire (US)
Oral Presentation Will be Held on September 13, 2007 at the 14th
International Symposium on Hepatitis C Virus & Related Viruses
to be Held in Glasgow, Scotland VALLEY COTTAGE, New York, September
6 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.
(NASDAQ:XTLBNASDAQ:LSE:NASDAQ:XTLNASDAQ:TASE:NASDAQ:XTL) announced
today that a late breaker abstract, entitled "Potent Small Molecule
HCV Inhibitors Affecting NS5A-dependent Functions," was selected
for oral presentation at the 14th International Symposium on
Hepatitis C Virus & Related Viruses (http://www.hcv2007.com/).
The presentation will take place at 10:30 Greenwich Mean time on
Thursday, September 13, 2007, and a press release outlining the
data presented will be released by the Company shortly thereafter.
The compounds that will be presented at the conference emerged from
the Company's DOS program, aimed at discovering novel hepatitis C
inhibitors applying a unique chemistry technology called Diversity
Oriented Synthesis. The DOS program was acquired by the Company in
late 2005. ABOUT XTL BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals
Ltd. ("XTL") is engaged in the development of therapeutics for the
treatment of neuropathic pain and hepatitis C. XTL is developing
Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for
the treatment of diabetic neuropathic pain. XTL is also developing
several novel pre-clinical hepatitis C small molecule inhibitors.
XTL also has an active in-licensing and acquisition program
designed to identify and acquire additional drug candidates. XTL is
publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(LSE:XTL)(TASE:XTL). Contact: Ron Bentsur Chief
Executive Officer Tel: +1-845-267-0707 ext. 225 DATASOURCE: XTL
Biopharmaceuticals Ltd CONTACT: Contact: Ron Bentsur, Chief
Executive Officer, Tel: +1-845-267-0707 ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024